Beam Therapeutics Inc (BEAM) Stock Price, Quote & News

Company Profile

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. It also intends to develop BEAM-103, an anti-CD117 monoclonal antibody, a...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 327 8775

Website: beamtx.com

Address:

238 Main Street, Cambridge, United States

_MR_BESTMAN_ Jan. 6 at 3:32 PM

$RGC $ZETA $TECK $BEAM

0 · Reply

EingeLTrade Jan. 6 at 3:14 PM

We got this early 😉 $BEAM

0 · Reply

THE_Monkey_Banana_Genius Jan. 6 at 3:14 PM

$GH $NTRA $CRSP $BEAM very nice day. Long. Any news?

0 · Reply

sogenerous Jan. 6 at 2:57 PM

$BEAM $ABCL nice day for bios

1 · Reply

RocroBio Jan. 6 at 2:51 PM

$NTLA $BEAM $EDIT $CRBU

1 · Reply

Elamenape2 Jan. 6 at 2:51 PM

$PRME $BEAM Going crazy!

0 · Reply

Noobnr1 Jan. 6 at 2:50 PM

$BEAM 🚀🚀🚀🚀 $PHAR 🙏🙏🙏 $GILD $PFE

0 · Reply

Buraku Jan. 6 at 2:48 PM

$BEAM anyone here?

0 · Reply

LinoeuSoul Jan. 3 at 4:22 PM

$BEAM Big geopolitical headline over the weekend (Venezuela/Maduro). For Monday: real risk-off for this ticker or just noise that weak hands will overreact to?

0 · Reply

Elamenape2 Jan. 1 at 10:04 PM

$CRSP $BEAM $PRME $EDIT

0 · Reply

Beam Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference

Dec 6, 2025, 8:00 AM EST - 4 weeks ago

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

Dec 4, 2025, 2:39 PM EST - 4 weeks ago

Beam Therapeutics: Strong Buy On BEAM-101 Progress And In Vivo LNP Shots On Goal

Nov 12, 2025, 7:00 AM EST - 7 weeks ago

Beam Therapeutics to Participate in 2025 Jefferies London Healthcare Conference

Nov 4, 2025, 7:00 AM EST - 2 months ago

Beam Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Updates

Nov 3, 2025, 9:00 AM EST - 2 months ago

Beam Therapeutics to Present Updated Data from BEACON Phase 1/2 Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Oct 22, 2025, 10:19 AM EDT - 2 months ago

Beam Therapeutics: SCD Catalysts Have Untapped Upside Potential

Sep 9, 2025, 9:54 AM EDT - 4 months ago

Beam Therapeutics Inc. (BEAM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Sep 9, 2025, 4:51 AM EDT - 4 months ago

Beam Therapeutics Inc. (BEAM) Presents At H.C. Wainwright 27th Annual Global Investment Conference Transcript

Sep 3, 2025, 8:38 PM EDT - 4 months ago

Beam Therapeutics Inc. (BEAM) Presents At Citi's Biopharma Back To School Conference Transcript

Aug 25, 2025, 7:00 AM EDT - 4 months ago

Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences

Aug 14, 2025, 7:00 AM EDT - 5 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

Aug 5, 2025, 7:00 AM EDT - 5 months ago

Beam Therapeutics Reports Second Quarter 2025 Financial Results and Provides Update on BEAM-302 Development Progress in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 20, 2025, 10:07 AM EDT - 7 months ago

Beam Therapeutics: Progress Of BEAM-101 Presses Forward With H2 2025 Data Releases

Jun 13, 2025, 7:00 AM EDT - 7 months ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

Jun 3, 2025, 7:00 AM EDT - 7 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

May 29, 2025, 4:01 PM EDT - 7 months ago

Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 14, 2025, 9:30 AM EDT - 8 months ago

Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

May 13, 2025, 7:00 AM EDT - 8 months ago

Beam Therapeutics to Participate in 2025 RBC Capital Markets Global Healthcare Conference

May 12, 2025, 4:01 PM EDT - 8 months ago

Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

May 6, 2025, 7:00 AM EDT - 8 months ago

Beam Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights

Apr 5, 2025, 7:00 AM EDT - 9 months ago

Beam Therapeutics Presents Additional Data for BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD) at 2025 Alpha-1 Foundation 7th Global Research Conference and 10th Patient Congress

Mar 31, 2025, 2:25 PM EDT - 10 months ago

Biotech stocks plunge as FDA's Peter Marks resigns over RFK Jr. dispute, Moderna and Beam Therapeutics hit hard

MRNA

Mar 27, 2025, 4:01 PM EDT - 10 months ago

Beam Therapeutics Announces Clearance of Investigational New Drug Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD) by the United States (U.S.) Food and Drug Administration

Mar 21, 2025, 1:13 PM EDT - 10 months ago

Upgrading Beam Therapeutics: Promising BEAM-302 Data Opens Door For Durable Gene Therapy

Mar 10, 2025, 9:07 AM EDT - 10 months ago

Gene Edit Biotech Beam Therapeutics Touts Encouraging Data From Early-Stage Gene Therapy Study In Genetic Disorder, Raises $500 Million Via Equity

Mar 10, 2025, 6:01 AM EDT - 10 months ago

Beam Therapeutics Announces Pricing of Underwritten Offering

Mar 10, 2025, 6:00 AM EDT - 10 months ago

Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

Feb 25, 2025, 7:00 AM EST - 11 months ago

Beam Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Reiterates Anticipated Catalysts

Feb 24, 2025, 7:00 AM EST - 11 months ago

Beam Therapeutics to Participate in Upcoming March 2025 Investor Conferences

Jan 30, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference

Jan 23, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR

Jan 13, 2025, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts

Dec 8, 2024, 1:45 PM EST - 1 year ago

Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting

Dec 7, 2024, 11:30 AM EST - 1 year ago

Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting

Dec 6, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

Dec 4, 2024, 7:00 AM EST - 1 year ago

Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

Nov 12, 2024, 4:01 PM EST - 1 year ago

Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference

Nov 7, 2024, 2:25 PM EST - 1 year ago

Beam Therapeutics: Additional BEAM-101 And ESCAPE Tech Data At ASH 2024 Makes This A Watch

Nov 5, 2024, 11:54 AM EST - 1 year ago

Beam Therapeutics Inc. (BEAM) Q3 2024 Earnings Call Transcript

Nov 5, 2024, 6:30 AM EST - 1 year ago

Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs

Oct 29, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual Meeting

Aug 6, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and Second Quarter 2024 Financial Results

Jul 15, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces Transition of Chief Financial Officer

Jun 26, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Announces First Patient Dosed in the Phase 1/2 Study of BEAM-302 in Alpha-1 Antitrypsin Deficiency (AATD)

Jun 14, 2024, 3:00 AM EDT - 1 year ago

Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease

May 30, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in Jefferies Global Healthcare Conference

May 14, 2024, 4:00 PM EDT - 1 year ago

Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress

May 8, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics to Participate in RBC Capital Markets 2024 Global Healthcare Conference

May 7, 2024, 6:30 AM EDT - 1 year ago

Beam Therapeutics Reports Pipeline Updates and First Quarter 2024 Financial Results

_MR_BESTMAN_ Jan. 6 at 3:32 PM

$RGC $ZETA $TECK $BEAM

0 · Reply

EingeLTrade Jan. 6 at 3:14 PM

We got this early 😉 $BEAM

0 · Reply

THE_Monkey_Banana_Genius Jan. 6 at 3:14 PM

$GH $NTRA $CRSP $BEAM very nice day. Long. Any news?

0 · Reply

sogenerous Jan. 6 at 2:57 PM

$BEAM $ABCL nice day for bios

1 · Reply

RocroBio Jan. 6 at 2:51 PM

$NTLA $BEAM $EDIT $CRBU

1 · Reply

Elamenape2 Jan. 6 at 2:51 PM

$PRME $BEAM Going crazy!

0 · Reply

Noobnr1 Jan. 6 at 2:50 PM

$BEAM 🚀🚀🚀🚀 $PHAR 🙏🙏🙏 $GILD $PFE

0 · Reply

Buraku Jan. 6 at 2:48 PM

$BEAM anyone here?

0 · Reply

LinoeuSoul Jan. 3 at 4:22 PM

$BEAM Big geopolitical headline over the weekend (Venezuela/Maduro). For Monday: real risk-off for this ticker or just noise that weak hands will overreact to?

0 · Reply

Elamenape2 Jan. 1 at 10:04 PM

$CRSP $BEAM $PRME $EDIT

0 · Reply

foreverbullishfuture Dec. 31 at 10:41 PM

$BEAM.X into the new year. $BEAM after every dip comes the rip get on board now!!

0 · Reply

AbovetheGreenLine Dec. 31 at 8:27 PM

Swing Trade Buy on the Close for Heartbeam Inc. $BEAM. https://abovethegreenline.com/wp-content/uploads/2021/01/ST-1.jpg https://zpr.io/Wau

0 · Reply

ZacksResearch Dec. 31 at 3:23 PM

Cutting-edge science — but real risks ahead ⚠️🧬 $BEAM is advancing its base-editing pipeline, highlighted by risto-cel studies and FDA designations, but it still has no approved products and faces rising competition as the field heats up. Is the pipeline progress enough to offset the execution risk? Get the full bull/bear view here 👉 https://www.zacks.com/stock/news/2810780/can-beams-gene-editing-pipeline-create-long-term-value-amid-rivalry?cid=sm-stocktwits-2-2810780-teaser-27001&ADID=SYND_STOCKTWITS_TWEET_2_2810780_TEASER_27001

0 · Reply

ZacksResearch Dec. 31 at 2:23 PM

$BEAM up 58.7% in 6 months — outperforming the industry, sector, and S&P 500 🚀 💡 Proprietary base-editing tech shows promise with risto-cel in SCD 🔬 Expansion into genetic diseases like GSD1a and AATD 📉 Trading at a P/B ratio of 2.92, below the industry's 3.65 Discover the full story here 👉 https://www.zacks.com/stock/news/2810780/can-beams-gene-editing-pipeline-create-long-term-value-amid-rivalry?cid=sm-stocktwits-2-2810780-body-26978&ADID=SYND_STOCKTWITS_TWEET_2_2810780_BODY_26978

0 · Reply

EingeLTrade Dec. 30 at 11:48 PM

$BEAM looks so beautiful into 2026 🤩

0 · Reply

Windytimes Dec. 29 at 5:49 PM

$CRBU $PRME $BEAM investors- wishing for a positive 2026

1 · Reply

GLPHOTOX Dec. 29 at 12:35 AM

$BEAM So, 2026 is almost here, what are your favorite 3 stock pics for next year

1 · Reply

K3NW00D Dec. 26 at 11:42 AM

$BEAM.X asia waiting for fiscal year to end before getting into new tokens like $BEAM on their exchanges. This could well be a 10-15x in the next run.

0 · Reply

W15E Dec. 25 at 11:58 PM

$BEAM looks $PRME d to get $CRSPY soon

0 · Reply

REITRealm Dec. 25 at 4:24 PM

$BEAM Market behavior suggests the name is transitioning from speculation toward proof‑based evaluation. Cash flow visibility will determine how patient investors remain. Any disconnect between guidance and outcomes will magnify skepticism. Patience is reasonable — but it must be matched by tangible progress.

0 · Reply

VVDB Dec. 25 at 2:57 AM

$BEAM Bullish! https://youtu.be/hwTSgFpWzQ8?si=dOTl7X4YYbJtEK2O

0 · Reply

SonnetSpeculator Dec. 24 at 11:56 AM

$BEAM Forward visibility remains uneven as progress validates the underlying thesis beyond narrative appeal. Long-term optimism depends on disciplined follow-through.

0 · Reply

Market Cap	2.75B
Revenue (ttm)	63.52M
Net Income (ttm)	-376.74M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-593.10%
Debt to Equity Ratio	0.00

Volume	2,077,800
Avg Vol	1,912,114
Day's Range	N/A - N/A
Shares Out	101.48M
Stochastic %K	49%
Beta	2.07
Analysts	Strong Sell
Price Target	$45.33